Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Ongoing discussions with the Federal Trade Commission regarding Tyco's pending acquisition of Bard under a $3.2 bil. May deal will delay completion, which is now not expected before the first quarter of 2002, Bard says. The merger, which had been expected to close by year-end, likely has drawn scrutiny of overlap in the urology field, mainly in areas such as Foley catheters, and could result in a possible divestiture of part of the business...

You may also be interested in...


Ongoing discussions between Tyco and the Securities and Exchange Commission regarding the anti-trust implications of its $3.2 bil. agreement to buy C.R. Bard will push the anticipated closing date for the merger from Jan. 31 to March 31 (1"The Gray Sheet" Nov. 19, 2001, In Brief)...

Bio-Thera Gets Chinese Nod To Proceed On Ustekinumab

China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.

Can Synthetic CBD Overcome Cannabis Stigma And Break EU Novel Foods Deadlock?

Czech firm CBDepot has filed a novel food application for synthetically made CBD in Europe, which it hopes regulators will find more palatable than those for supplements derived from the cannabis plant.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts